Publications

Patel C, Vette K, Dalton L, Dey A, Hendry A, Hull B, McIntyre P, Macartney K, Beard F. Assessment of the first 5 years of pharmacist-administered vaccinations in Australia: learnings to inform expansion of services. Public Health Research and Practice 2024;34:3432420. doi: 10.17061/phrp3432420. [Full text]

Tinessia A, Clark K, Randell M, Leask J, King C. Strategies to address COVID-19 vaccine hesitancy in First Nations peoples: a systematic review. Global Health Action 2024;17:2384497. doi: 10.1080/16549716.2024.2384497 (Epub) . [Full text]

Loe MW, Soenong H, Lee E, Li-Kim-Moy J, Williams PC, Yeo KT. Nirsevimab: alleviating the burden of RSV morbidity in young children. Journal of Paediatrics and Child Health 2024. doi: 10.1111/jpc.16643 (Epub) . [Full text]

McDonald E, Pittet LF, Barry SE, Bonten M, Campbell J, Croda J, Croda MG, Dalcolmo MP, Davidson A, de Almeida E Val FF, Dos Santos MG, Gardiner MK, Gell MG, Gwee A, Krastev MA, Lacerda MVG, Lucas M, Lynn DJ, Manning L, McPhate MN, Perrett KP, Post JJ, Prat-Aymerich C, Quinn MLE, Richmond PC, Wood NJ, Messina NL, Curtis N; BRACE Trial Consortium Group. Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: insights from prospectively collected data in the BRACE trial. Journal of Infection 2024:106267. doi: 10.1016/j.jinf.2024.106267 (Epub). [Full text]

Reynolds R, Tay E, Dymock M, Deng L, Glover C, Lopez LK, Huang YA, Cashman P, Leeb A, Marsh JA, Snelling T, Wood N, Macartney K. Short-term active safety surveillance of the Spikevax and Nuvaxovid priming doses in Australia. Vaccines 2024; 12:971. doi: 10.3390/vaccines12090971 (Epub). [Full text]

Salter SM, Li D, Trentino K, Nissen L, Lee K, Orlemann K, Peters I, Murray K, Leeb A, Deng L. Safety of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of Australian community pharmacy vaccinations. Vaccines 2022;10:2017. doi: 10.3390/vaccines10122017. [Full text]

Tay E, Dymock M, Lopez L, Glover C, Huang YA, Bakar KS, Snelling T, Marsh JA, Wu Y. Applying causal inference and bayesian statistics to understanding vaccine safety signals using a simulation study. NPJ Vaccines 2024;9:163. doi: 10.1038/s41541-024-00955-4. [Full text]

Howlett M, Mayfield HJ, McPherson B, Rigby L, Thomsen R, Williams SA, Pilotte N, Hedtke SM, Graves PM, Kearns T, Naseri T, Sheridan S, McLure A, Lau CL. Molecular xenomonitoring as an indicator of microfilaraemia prevalence for lymphatic filariasis in Samoa in 2019. Parasites and Vectors 2024;17:382. doi: 10.1186/s13071-024-06463-7. [Full text]

Hasan T, Lynch M, King C, Wehbe C, Plymoth M, Islam MS, Iannuzzi T, Dao A, Lai J, Martiniuk A, Desai S, Sheel M. Vaccine-preventable disease outbreaks among healthcare workers: a scoping review. Clinical Infectious Diseases 2024;79:555-561. doi: 10.1093/cid/ciae209. [Full text]

Jayasinghe S, Williams PC, Macartney KK, Crawford NW, Blyth CC. Assessing the impact of pneumococcal conjugate vaccine immunization schedule change from 3+0 to 2+1 in Australian children: a retrospective observational study. Clinical Infectious Diseases 2024:ciae377. doi: 10.1093/cid/ciae377 . [Full text]